Interleukin 1 (IL-1) plays a central role in the regulation of the body's response to infectious and inflammatory stimuli. Recent evidence has shown that human platelets express a cell associated form of this proinflammatory cytokine very rapidly following activation. Since one of the earliest events in inflammation is frequently the rapid adhesion of platelets to injured endothelium, it was of interest to determine whether platelets express IL-1 in a functionally relevant form that can alter the phenotype of human endothelial cells in vitro. Thrombin activated platelets induced significant expression of the adhesion molecule intercellular adhesion molecule 1, as well as secretion of the IL-1 inducible cytokines Ib6 and granulocyte macrophage colony stimulating factor by cultured human umbilical cord and saphenous vein endothelial cells. This was inhibited by prior treatment of the platelets with antibody specific for Ibl, These results suggest that platelet delivered IL-1 might initiate and regulate some of the earliest phases of the inflammatory response. An additional observation of interest was differential induction of endothelial leucocyte adhesion molecule I by activated platelets on saphenous vein but not umbilical vein endothelial cells, which suggests functional heterogeneity of the endothelial cells.
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T he vascular endothelium normally maintains a thromboresistant luminal surface but following injury there is a rapid loss of this anticoagulant state, with consequent platelet binding and activation (1, 2) . Endothelial cells also play an important role in the inflammatory response, where they undergo significant functional changes. These include increased expression of adhesion promoting molecules such as intercellular adhesion molecule-1 (ICAM-1) 1 and endothelial leucocyte adhesion molecule-1 (ELAM-1), thus leading to the binding and extravasation of leukocytes, as well as the release of soluble mediators (3, 4) . Many of these changes can be mimicked in vitro by the addition of recombinant cytokines such as IL-1 and TNF to endothelial cell monolayers (5, 6) . In addition local injection of Ibl or TNF results in rapid recruitment of leukocytes from the blood (7, 8) , and these cytokines can be detected at sites of inflammatory lesions, e.g., autoimmune sites and atherosclerotic lesions (9) (10) (11) . These studies predict an important role for such cytokines in vivo in controlling the phenotype and function of endothelial and other inflammatory cells at sites of inflamma-1 Abbreviations used in this paper: ADP, adenosine diphosphate; ELAM-1, endothelial leukocyte adhesion molecule 1; GM-CSF, granulocyte macrophage colony-stimulating factor; HUVEC, human umbilical vein; ICAM-1, intercellular adhesion molecule 1; SAVEC, adult saphenous vein. tion and immunological challenge. However the source and regulation of their production at the site of injury, especially in its earliest stages prior to leucocytic adherence and extravasation, has not been dearly identified.
One of us (C. M. Hawrylowicz) has recently demonstrated that following activation, human platelets are rapidly induced to express a cell associated form of the cytokine Ibl (12) . Agonists that stimulate its expression in vitro include adenosine diphosphate (ADP), collagen and thrombin, which are known to be present at sites of injury. Based on the importance of II.,1 in modulating endothelial function both in vitro and in vivo (5-8), we have now examined whether platelet derived II.-1 is present in a functionally relevant form that might thus provide an important early signal for the activation of the endothelium at sites of inflammation.
Materials and Methods
Plateletpre~ration. Washed platdets were prepared from freshly drawn venous blood treated with 1/10 volume of citrate anticoagulant as previously described (12) . Hatelet preparations were contaminated with less than 0.1% red blood cells and no obvious (less than 0.01%) mononuclear cell contamination was observed. Washed platelet preparations were activated with 0.5-1 U/ml thrombin prepared from human plasma (Sigma Chemical Co., Poole, UK) for 2-4 min at room temperature.
Endothelial Cell Culture. Human endothelial cells were derived from umbilical vein or adult saphenous vein by collagenase digestion as previously described (13) , and grown on RPMI-1640 medium supplemented with 15-30/~g/ml endothelial growth factor (Sigma Chemical Co., 50 U/ml sodium hepafin and 10% newborn (NBS) plus 10% FCS. Calls were routinely used between the second and fifth passages. 1 or 2 d before an experiment endothelial cells were plated on gelatin coated 24-well microtiter plates at a density of approximately 5 x 104 -10 s cells per well. Immediately before stimulation endothelial monolayers were washed 2-3 times in prewarmed serum free medium. Fig. 1 A demonstrates the purity of endothelial preparations by staining with two markers for endothelial surface antigens, antibody specific for gplla (CLB-HEC75; a kind gift from Dr. J.A. van Mourik, Central Laboratory of the Netherlands Red Cross Blood Transfusion, Amsterdam, The Netherlands) and Ulex Europaeus-1 lectin coupled to fluorescein isothiocyanate (ULEX-FITC; Sigma Chemical Co.).
Endothelial Cell Stimulation. Endothelial cells were cultured with 2-5 x 107 resting or thrombin activated platelets, superuatant from an equivalent number of activated platelets, thrombin (at a final concentration of 0.05-0.1 U/ml, and comparable to that added in the activated platelet preparations), the indicated concentrations of ri1r (specific activity 1.6 x 108 U/mg, kindly provided by Dr. P. Lomedico, Hoffman La Roche, Nutley, N.J.), or medium alone for 6-24 h at 37~ in a 5% CO2 humidified atmosphere in a final volume of I ml RPMI-1640 with 10-15% FCS.
Anti-Cytokine Antibodies. In the experiments described in Fig. 1 C and 3 B and/3, mouse mAb to human Iblc~ (Dai Nippon, Japan; IgG1) was used at 4 #g/ml and goat antiserum specific for human IDIB at a dilution of 1:800 (Immunex Corporation, Seattle, WA). Control irrelevant antibodies used were a 1:800 dilution of normal goat serum (Sigma Chemical Co.) and 5/zg/ml monoclonal mouse anti-human TNF (TNF-E, Genentech; IgG1). In Fig. 2 B a 1:100 dilution of polyclonal rabbit antiserum specific for Ibl~, IL-I~, or a combination of both (kindly donated by Immunex Corporation) were used to pretreat activated platelets before the addition to endothelial cell stimulation cultures and giving a final individual serum concentration of 1/1,000 in culture. Alternatively, polyclonal rabbit antiserum specific for Ib4 (used at 20/~g/ml) final concentration, Immunex Corporation) were used as control. Additional control antibodies used included goat antiserum specific for human II+-6 (kindly provided by Dr. L. Aarden, Central Laboratory of the Netherlands Red Cross Blood Transfusion, Amsterdam, The Netherlands) and rabbit antiserum to human transforming growth factor beta (TGFB) generated in this laboratory by Dr. E. Abney.
Immunostaining. Following culture endothelial cells were extensively washed in prewarmed HBSS and incubated with versene for 15-30 rain at 37~ at which time they detached readily from the tissue culture plate, and were washed twice. Cells (approximately 10 s per group) were stained for ICAM-1 expression with a 1:1000 dilution of mouse ascites of antibody 1H4, (kindly donated by Dr. A. Boyd, Melbourne, Australia), followed by 10 #g/ml goat antibody specific for mouse immunoglobulin (Ig) coupled to FITC (Southern Biotechnology Associates, Birmingham, AL). Alternatively cells were stained for the expression of ELAM-1 antigen with a 1:3000 dilution of ammonium sulphate precipitated ascites containing mouse antibody H18/7 (generously provided by Drs. M. Munro and M. Gimbrone, Boston, MA) and then the goat anti-mouse Ig FITC detection reagent. All cell groups were also stained with second layer reagent alone (goat anti-mouse Ig FITC). Control staining was performed with 100 ~1 culture supernatant from HB55 cells (American Tissue Culture Collection, Rockville, MD) containing antibody specific for HLA-DR class II antigen or a control mouse IgG2a FITC reagent (Becton Dickinson and Co.) used at 10/~g/ml. All staining was performed on ice in the presence of 0.02% sodium azide. Fluorescence analysis was performed by FACSCAN (Becton-Dickinson and Co., Mountain View, CA) and data is presented in the form of FACSCAN profiles ( Cytokine Assays. Endothelial cell culture supernatants were harvested after overnight culture, filtered to eliminate platelet or endothelial cell contamination and either used immediately or frozen until used in the bioassays described below. IL-6 was measured using the B9 bybridoma cell line kindly provided by Dr. L. Aarden. Briefly, 2,000 B9 cells were cultured with either recombinant Ib6 (generously provided by Interpharm Laboratories, Israel; specific activity 5.65 x 10 + U/rag) or 2-or 3-fold fold serial dilutions of the endothelial supernatants described above in triplicate wells to give a final volume of 200/~1 in RPMI-1640 with 10% FCS. After 3 d incubation at 37~ the cells were pulsed with 0.5 #Ci tritiated thymidine (3H-thymidine) for the final 4 h of culture, harvested using a multi-well cell harvester (Skatron), and counted using a beta-plate system (Pharmacia, UK). The standard deviation of mean counts from triplicate wells rarely exceeded 10%. GM-CSF was assessed in an assay utilizing cells kindly provided by Genetics Institute, Boston, MA and with help from Dr. C. Haworth (Chafing Cross Sunley Research Centre, London, UK). Briefly, 2 x 104 MO7-E cells were cultured for 3 d with endothelial derived supernatant or rGM-CSF (a kind gift of Dr. A. Krumwich, Behringwerke AG, Marburg; specific activity 4.5 x 107 CFU/mg) and measured for growth by incorporation of [3H]thymidine during the last 6 h of culture. Data for both Ib6 and GM-CSF activity measurements are presented as units per ml of cytokine activity where the values of a minimum of 2, and up to 6, serial dilutions of endothelial supernatant were computed from a standard curve of recombinant cytokine and these values presented as the mean U/ml _+ SD. Specificity of the bioactivity present in endothelial culture supernatants was ascertained by the addition of neutralising antibodies specific for IL-6 (goat anti-human IL-6, kindly provided by Dr. L. Aarden) and GM-CSF (rabbit antiserum generated by Drs. C. Haworth and E. Abney at Chafing Cross Sunley Research Centre, London, UK), respectively.
Results and Discussion

Selective Induction of Adhesion Molecules on Endothelial Cells by Platelet-Derived ILl. ICAM-1 is important for the adhe-
sion of lymphocytes and monocytes to endothelium and its expression is upregulated both in vivo and in vitro on endothelial cells by recombinant (r)Ibl (5, 14) . In the current experiments, and as previously reported, both human umbilical vein (HUVEC) and adult saphenous vein (SAVEC) endothelial cell monolayers responded to rib1 by enhanced 1CAM-1 expression (Fig. 1 B and C) , as measured by FAC-SCAN analysis of specific binding of mAb 1H4. Thrombin activated platdets, when used to stimulate HUVEC or SAVEC, also induced a significant increase in surface ICAM-1 antigen expression. No significant difference was observed in the capacity of HUVEC or SAVEC to respond to platdets for enhanced ICAM-1 expression. Indeed while HUVEC are the most widely used modal of endothelium, there may be 786
Platelet-derived Interleukin 1 Modulates Endothelial Cell Function differences due to their foetal nature and for this purpose the two cell types were therefore compared throughout. Our earlier data indicated that I1-1 was expressed predominantly by activated and not resting platelets (12) . In the present study unstimulated platelets induced much lower increases in ICAM-1 expression on HUVEC (Fig. 2 A) , although some variability was observed between experiments. In 7 experiments the fluorescent intensity (~ + SE of the mean) of staining for ICAM-1 on unactivated HUVEC was 33 _+ 27, on cytokine induced HUVEC 198 _ 91, on HUVEC cultured with resting platelets 58 _+ 27 or activated platelets 149 +_ 42. Supernatants from activated platelets did not increase ICAM-1 expression on HUVEC, demonstrating a requirement for a membrane associated function expressed on activated platelets (Fig. 2 A) . Finally, platelet agonists such as thrombin failed to stimulate ICAM-1 expression (Fig. 2  A) or influence ICAM-1 induction by rlL,1 (data not shown). A similar pattern of responsiveness was observed with SAVEC.
Earlier studies calculated that 1.8 x 107 platelets induced a response comparable to 1 U/ml rlL-1 in the D10.G4.1 functional assay for IL-1 (12) . This agrees with the estimate made in the present study, where activated platelets were compared with rI1-1 for the capacity to enhance ICAM-1 antigen expression (Fig. 2 A) . However this is a rough estimate since variation between platelet samples from different individuals was regularly observed (data not shown). This is in line with recent studies demonstrating similar individual variation in I1-1 production by peripheral blood derived monocytes from different donors (15) .
To determine whether IL-1 or other platelet derived products mediated ICAM-1 induction, activated platelets were pretreated with antibodies to I1-1ol and IL-13 before stimulation of HUVEC or SAVEC. The combination of both anti-I1-1 antibodies completely abrogated the capacity of activated platelets to increase HUVEC ICAM-1 levels above background (Fig. 2 B) . A control antibody specific for IL-4 had no significant effect (Fig. 2 B) , and in additional experiments normal rabbit antiserum or antibodies to II-6 and TNF had no inhibitory effect on platelet induced ICAM-1 expression. Similar results were obtained with SAVEC (Fig. 1 C) . The requirement for antisera to both IL-lo~ and I1-13 to obtain significant inhibition of platelet stimulated endothelial function was confirmed by the failure to obtain good inhibition with either alone (Fig. 2 B) , and by titrating one antibody in the presence of a fixed concentration of the second (data not shown), and represents data reproduced with antisera from two separate sources (Fig. 1 C versus 2 B) . This HUVEC or SAVEC were cultured with medium, 1-100 ng/ml rlL-1B or 2 x 10; thrombin activated platelets for 6-8 h, at which time they were stained for the expression of ELAM-1 antigen and ICAM-1 antigen as described in Materials and Methods. 10 ~ thrombin activated platelets were pretreated with medium alone or polyclonal rabbit antiserum specific for IL-la, IblB, or a combination of both, or polyclonal rabbit antiserum specific for IL-4 before addition to confluent endothelial monolayers. HUVEC were then stained as described in Materials and Methods for ICAM-1 antigen expression (hatched bars).
Control staining was performed for HLA-DR (Fig. 2 A; clear bars) , or a control mouse IgG2a FITC reagent (Fig. 2 B; was surprising since earlier studies measuring platelet derived II.-1 activity in the D10.G4.1 T cell growth assay observed that mAbs specific for IL-lo~ and IL-13 inhibited 10-20% and 80-90% ofplatelet activity, respectively (12) . The reason for this difference is unclear, but is most readily explained by differences in the antibody preparations themselves. Plans to complete this study by showing the capacity of activated platelets to induce expression of a second IL-1 inducible adhesion molecule ELAM-1 (16), uncovered a surprising difference between HUVEC and SAVEC. Although SAVEC responded to activated platelets by the upregulation of ELAM-1 antigen in an IL-1 dependent manner, HUVEC selectively failed to upregulate the ELAM-1 antigen, as demonstrated in Table 1 , despite clear enhancement of ICAM-1 measured in the same assays. The reason for this selectivity does not appear to represent presentation of insuf~cient IL-1 to HUVEC since increasing platelet number had no effect, nor was there any difference in the concentration of rlL-1 required to induce ELAM-1 or ICAM-1 expression on the same HUVEC population (data not shown). This suggests heterogeneity of function of endothelial cells derived from different sources and may represent differential sensitivity to other platelet products (inhibiting ELAM-1 induction in HUVEC but not SAVEC) which is currently under investigation.
Platelet-Derived ILl Stimulates Secretion of Cytokines by CulturedEndothelial Cells.
The addition of purified rlL-1 in vitro stimulates the release of a number of chemotactic and cytokine activities by endothelial cells (5, 6) . To test whether platelets modulated other parameters of endothelial IL-1 inducible function, secretion of IL-6 and granulocyte macrophage colonystimulating factor (GM-CSF) by endothelial cells was assessed following stimulation with activated platelets. Fig. 3 A and C demonstrate that activated platelets induced significant levels of bioactive II.,6 and GM-CSF production by HUVEC following 1 day of coculture as measured in the B9 and MO7E bioassays, respectively. The activity of supernatants derived from endothelial cells cultured with activated platelets and testing positive in IL-6 and GM-CSF bioassays were neutralized by addition of anti-IL-6 or anti-GM-CSF antibodies to the appropriate bioassay. Resting platelets induced significant but lower levels of these cytokines as demonstrated in both the GM-CSF and IL-6 bioassay data in Fig. 3 A and C. As predicted from the membrane bound nature of platelet IL-1, in all experiments performed supernatant derived from activated platelets had no cytokine inducing capacity. Supernatants derived from platelets cultured alone, in the absence 788 Platelet-derived Interleukin 1 Modulates Endothelial Cell Function
